DelveInsight’s “Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology and the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Parainfluenza Virus Infection Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Parainfluenza Virus Infection Market Size

 

Key Takeaways from the Parainfluenza Virus Infection Market Report

• In November 2024:- Ansun Biopharma Inc.:- All eligible subjects in the PoI with a respiratory infection due to any SAD-RV infection except PIV. Eligible subjects with both PIV and an additional concurrent SAD-RV, will be enrolled for either Cohorts 2 or 3 depending on their age. There is no lower age limit for this cohort.
• According to DelveInsight estimations, 2,709,923 Cases of Parainfluenza virus infection were found in 2023 in the 7MM.
• As per DelveInsight’s estimations, the total number of incident cases of parainfluenza virus in the United States were 1,456,399 in 2023 and are projected to increase during the forecast period.
• According to DelveInsight’s estimates, the total Incident Cases of parainfluenza virus infection in EU4 and the UK were found to be 991,115 in 2023. The highest proportion of parainfluenza virus infection cases was reported in Spain among the EU4 countries, while the least number of cases was found in the UK.
• The estimates show the number of parainfluenza virus infection cases in Japan was found to be approximately 262,409 in 2023, which is estimated to increase by 2034.
• The leading Parainfluenza Virus Infection Companies such as Ansun Biopharma, AlloVir, and others.
• Promising Parainfluenza Virus Infection Therapies such as DAS181, MEDI-534, and others.

 

Stay ahead in the competitive landscape of the Parainfluenza Virus Infection Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Parainfluenza Virus Infection Treatment Market Size

 

Parainfluenza Virus Infection Epidemiology Segmentation in the 7MM

• Total Parainfluenza Virus Infection Incident Cases
• Parainfluenza Virus Infection Serotype-Specific Incident Cases
• Parainfluenza Virus Infection Gender-specific Incident Cases
• Parainfluenza Virus Infection Age-specific Incident Cases

 

Download the report to understand which factors are driving Parainfluenza Virus Infection epidemiology trends @ Parainfluenza Virus Infection Prevalence

 

Parainfluenza Virus Infection Emerging Drugs

• DAS181: Ansun Biopharma

DAS181 is a first-in-class recombinant sialidase protein that is designed to remove sialic acids located on the surface of epithelial cells lining the human respiratory tract. These sialic acids are naturally present on cell surfaces and are needed by some viruses for viral entry into cells. Cleavage of sialic acid inactivates the mechanism for viral entry and infection, interrupting the virus lifecycle and giving patients the chance to recover. DAS181 has demonstrated antiviral activity against three of the four major respiratory viruses, influenza virus (IFV), parainfluenza virus (PIV), and metapneumovirus (MPV), as well as human enterovirus-68 (EV-68).

 

• ALVR106: AlloVir

ALVR106 is an allogeneic, off-the-shelf, multivirus-specific VST investigational therapy designed to target infections and diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrate that ALVR106 has antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. (AlloVir, 2024).

 

Parainfluenza Virus Infection Market Outlook

Presently, the primary approach to treating HPIV infection involves supportive care, except for croup, where corticosteroids have been identified as beneficial. Novel drugs like DAS181 show promise for treating severe cases in immunocompromised patients and are currently undergoing development. Despite continuous endeavors, effective treatment options for PIV infection remain lacking, with no approved medications addressing this critical gap in care. Specifically, there is still no FDA-approved cure or antiviral medication designated for treating HPIV infection.

 

Discover the future of Parainfluenza Virus Infection treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Parainfluenza Virus Infection Market Drivers and Barriers

 

Parainfluenza Virus Infection Companies

Ansun Biopharma, AlloVir, and others.

 

Parainfluenza Virus Infection Treatment Market

The Parainfluenza Virus Infection Treatment Market addresses the growing demand for therapies that manage and mitigate infections caused by the human parainfluenza viruses (HPIVs). These viruses are a leading cause of respiratory illnesses, particularly in young children, the elderly, and immunocompromised individuals. While HPIVs can cause mild cold-like symptoms in some, they are known to lead to more severe conditions such as croup, bronchiolitis, and pneumonia.

 

Explore the dynamics of the Parainfluenza Virus Infection Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Parainfluenza Virus Infection Ongoing Clinical Trials Analysis

 

Scope of the Parainfluenza Virus Infection Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Parainfluenza Virus Infection Companies- Ansun Biopharma, AlloVir, and others.
• Parainfluenza Virus Infection Therapies such as DAS181, MEDI-534, and others.
• Parainfluenza Virus Infection Therapeutic Assessment: Parainfluenza Virus Infection marketed and Parainfluenza Virus Infection emerging therapies
• Parainfluenza Virus Infection Market Dynamics: Parainfluenza Virus Infection market drivers and Parainfluenza Virus Infection market barriers
• Parainfluenza Virus Infection Unmet Needs, KOL’s views, Analyst’s views, Parainfluenza Virus Infection Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Report Introduction

3. Parainfluenza Virus Infection Market Overview by Therapies

4. Epidemiology and Market Methodology of PIV Infection

5. Executive Summary of PIV Infection

6. Key Events

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Emerging Therapies

11. Parainfluenza Virus Infection: The Seven Major Market Analysis

12. Key Opinion Leaders’ Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market